Research News

New treatment approach shows promise for relapsed Hodgkin’s lymphoma

BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1533 (Published 20 March 2015) Cite this as: BMJ 2015;350:h1533
  1. Jacqui Wise
  1. 1London

Adults with hard to treat Hodgkin’s lymphoma who were given brentuximab vedotin immediately after stem cell transplantation survived without the disease progressing for twice as long as those given placebo, a phase III randomised controlled trial published in the Lancet shows.1

Brentuximab vedotin, the first new drug for Hodgkin’s lymphoma in over 30 years, is an antibody attached to a powerful chemotherapy drug that targets the CD30 protein on Hodgkin’s lymphoma cells. It has recently been approved for relapsed or refractory Hodgkin’s lymphoma …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe